| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., Nov. 3, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarte... |
| 12 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has ... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., July 30, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quar... |
| 17 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the Madrigal Pharmaceuticals 2026 Stock Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Madrig... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., May 6, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter... |
| 28 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 22, 2026, the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) completed a process to reclassify the membership of the Board’s three classes of directors to achieve a more equal apportionment of... |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., Feb. 19, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quar... |
| 30 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
| 11 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., Nov. 4, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarte... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., Aug. 5, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quart... |
| 30 Jul 2025 |
8-K: Regulation FD Disclosure
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) |
| 22 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 20, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 24, 2025, the record date for the Annual Meeting, 22,203,282 shares of the Company’s common... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., May 1, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter... |
| 17 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 16, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into that certain Letter Agreement (the “Letter Agreement”) with Dr. Rebecca Taub, the Company’s Chief Medical Officer and President of Research and Development. P... |
| 11 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition
Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectively |
| 31 Oct 2024 |
8-K: Results of Operations and Financial Condition
Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy |
Loading...